Orphanet: IMPRES: A 24 week Randomized Placebo controlled, Double blind Multi centre Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study PhaseIII coordination
x

Cerca un network

* (*) campo obbligatorio

IMPRES: A 24-week Randomized Placebo-controlled, Double-blind Multi-centre Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (PhaseIII) (coordination)

IMPRES: A 24-week Randomized Placebo-controlled, Double-blind Multi-centre Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (PhaseIII) (coordination)

  • Tipo di network : Sperimentazioni cliniche internazionali
  • Distribuzione geografica : Mondiale
  • Ente(-i) finanziatore(-i) : -
  • Sponsor : -
  • Sito web
  • Coordinatore della sperimentazione clinica internazionale

  • NOVARTIS INTERNATIONAL AG
  • Novartis International AG
  • WSJ-103.4.26
  • 4002 BASEL
  • SVIZZERA
  • Piu informazioni
  • Telefono  : 0041 (0)61 324 1111
  • Fax  : 0041 (0)61 324 8001
Ultimo aggiornamento: Marzo 2011

Informazioni supplementari

Tutte le informazioni presenti nel sito non sostituiscono in alcun modo il giudizio di un medico specialista, l'unico autorizzato ad effettuare una consulenza medica ed esprimere un parere medico.